sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Anifrolumab

Medicine · Type I Interferon Receptor Antagonist

Anifrolumab

SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • Use of SAPHNELO is not recommended in these situations.
  • SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Do not take if
SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia.

What it is used for

Limitations of Use

The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.

Side effects, and when to stop

The following clinically significant adverse reactions are also discussed elsewhere in the labeling:

  • Serious Infections
  • Hypersensitivity Reactions Including Anaphylaxis
  • Malignancy

Who should not take it

SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia.

Other medicines and interactions

No formal drug interaction trials have been conducted.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Anifrolumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/anifrolumab

APA 7th

sofidex. (2026, August 2). Anifrolumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/anifrolumab

AMA 11th

Anifrolumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/anifrolumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.